Chris Hollowood, Syncona CEO (Syncona via YouTube)
Syncona takes write-down on SwanBio as biotech halves workforce to focus on one gene therapy
UK life sciences investor Syncona has taken a write-down on its investment in private gene therapy biotech SwanBio, part of a broader hit to its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
